Skip to content
Screener

Pre-Tax Income at other companies

Rogers Corporation logo
Rogers CorporationROG
$21.4M+131%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$74.9M-96.9%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$37.1M+252%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$6.47M+54.2%
Opko Health logo
Opko HealthOPK
-$13.4M+91.8%

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.07B+35.7%
Enterprise value$1.98B+25.5%
P/E6.6×-18.6×
P/S6.7×+0.8×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Income from operations46,34120,08387,76341,930
Interest income3,3933,1906,9086,759
Interest expense(948)(1,117)(1,960)(2,184)
Net income before income taxes48,78622,15692,71146,505
Income tax expense11,37264320,9421,648
Net income$37,414$21,513$71,769$44,857
Other comprehensive income:
Unrealized loss on available-for-sale securities(97)(80)(378)(258)

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's pre-tax income?
Aurinia Pharmaceuticals (AUPH) reported pre-tax income of $48.79M in Q2 2026.
How has Aurinia Pharmaceuticals's pre-tax income changed year-over-year?
Aurinia Pharmaceuticals's pre-tax income increased by 120.2% year-over-year, from $22.16M to $48.79M.
What is the long-term trend for Aurinia Pharmaceuticals's pre-tax income?
Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's pre-tax income has grown at a -10.8% compound annual growth rate (CAGR), from -$180.21M to $114.16M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Aurinia Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude